WALTHAM, Mass., Feb. 24, 2021 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced that
members of its management team will participate in two upcoming
virtual investor conferences:
- A panel at the Cowen 41st Annual Health Care Conference at
11:40 a.m. ET on Wednesday, March 3,
2021.
- A fireside chat at the Barclays Global Healthcare Conference at
3:35 p.m. ET on Tuesday, March 9,
2021.
A live webcast of the Barclays presentation can be accessed from
the Investor section of the Company's website at www.syndax.com,
where a replay of the event will also be available for a limited
time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. The Company's pipeline includes SNDX-5613, a
highly selective inhibitor of the Menin–MLL binding interaction,
axatilimab, a monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor, and entinostat, a class I
HDAC inhibitor. For more information, please
visit www.syndax.com or follow the Company
on Twitter and LinkedIn.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-301234357.html
SOURCE Syndax Pharmaceuticals, Inc.